Soaring Demand Set to Propel Iron Deficiency Injectable Market to $22.81 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Iron Deficiency Injectable Market Through 2025?
The injectable market dedicated to treating iron deficiency has experienced a robust expansion recently, projected to advance from a 14.06$ billion valuation in 2024 to 15.22$ billion by 2025, reflecting an $8.3% compound annual growth rate. This significant upward trend observed historically stems from several key factors, including the widespread need for iron deficiency anemia therapies, the increasing number of individuals undergoing bariatric surgery, the expanding patient pool comprising pediatric and adolescent demographics, and the rising incidence of pregnancy.

What's the Projected Size of the Global Iron Deficiency Injectable Market by 2029?
Anticipation surrounds the iron deficiency injectable sector, projecting substantial expansion in the forthcoming years, with its market value set to reach $22.81 billion by 2029, reflecting a compound annual growth rate (CAGR) of 10.6%; this projected upswing is fundamentally driven by factors such as the aging global population, various worldwide health campaigns, proactive governmental programs, the rising incidence of treatments for long-term ailments, and the swift need for iron restoration. Key developments anticipated across this forecasted timeframe encompass technological progress in iron compound creation, the integration of digital wellness platforms, ongoing therapeutic innovation within injectable iron deficiency treatment, and the increasing utilization of medications centered on iron.

View the full report here:
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Top Growth Drivers in the Iron Deficiency Injectable Industry: What's Accelerating the Market?
The continuing rise in the incidence of polycystic ovary* syndrome (PCOS) is anticipated to fuel the expansion of the market for iron deficiency injectables in the future. As a widespread endocrine condition impacting those with ovaries, predominantly women of childbearing age, PCOS frequently precipitates an excess of iron, leading to substantial menstrual hemorrhage and subsequent patient anemia; this condition is effectively managed through prescribed iron deficiency injections. To illustrate the scale, the World Health Organization, a specialized global health body, reported in June 2023 that PCOS impacts approximately 8 to 13 percent of women of reproductive age worldwide, with a staggering 70 percent of those affected remaining undiagnosed; consequently, this widespread prevalence of PCOS is the primary catalyst behind the escalating demand within the iron deficiency injectables sector.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp

What Trends Will Shape the Iron Deficiency Injectable Market Through 2029 and Beyond?
Major participants within the iron deficiency injectables sector are focusing efforts on innovating new treatments, exemplified by INJECTAFER, as a strategic move to solidify their market standing. A notable recent development occurred in June 2023 when Daiichi Sankyo Company, hailing from the US healthcare sphere, alongside US-based manufacturer American Regent Inc., introduced INJECTAFER (ferric carboxymaltose injection) for addressing iron deficiency, following its authorization by the United States Food And Drug Administration. This specific intravenous iron replacement treatment holds the distinction of being the initial and currently exclusive therapy approved by the FDA for adult individuals suffering from chronic, progressive heart failure. The regulatory clearance for INJECTAFER was substantially informed by an extensive review encompassing over 40 clinical studies featuring more than 8,800 subjects across numerous nations, further validating its established efficacy and safety profile in diverse patient populations, including both adults and children afflicted with iron-deficient anemia and concurrent heart failure.

What Are the Main Segments in the Iron Deficiency Injectable Market?
The iron deficiency injectablemarket covered in this report is segmented -

1) By Type: Iron Dextran; Iron Sucrose; Ferric Carboxymaltose
2) By Branded or Generics: Branded; Generics
3) By Application: Chronic Kidney Disease; Inflammatory Bowel Disease; Cancer; Other Applications
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran; High Molecular Weight Iron Dextran
2) By Iron Sucrose: Venofer
3) By Ferric Carboxymaltose: Injectafer; Ferinject

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12907&type=smp

Which Top Companies are Driving Growth in the Iron Deficiency Injectable Market?
Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH, Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.

Which Regions Will Dominate the Iron Deficiency Injectable Market Through 2029?
North America was the largest region in the iron deficiency injectable market in 2024. The regions covered in iron deficiency injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12907

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.